Drug intelligence / Profile preview

AT-019

Development stage: Preclinical
Lead developer: Elanco
Modality: Small Molecules

Overview

AT-019 is a preclinical, next-generation small molecule EP4 receptor antagonist developed for the treatment of pain and inflammation in veterinary applications, specifically in dogs and cats. It was originally developed by AskAt Inc. and subsequently in-licensed by Aratana Therapeutics, which aimed to expand its pipeline in pain management. Following Elanco Animal Health's acquisition of Aratana Therapeutics, AT-019 became part of Elanco's pipeline of product candidates.

Targets

PTGER4 (Prostaglandin E2 receptor EP4 subtype)

Beyond the preview

Go deeper on AT-019.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AT-019.

Explore the full profile